Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock: Insider Sanj Patel Sells 89,433 Shares

by · The Markets Daily

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA – Get Free Report) CEO Sanj Patel sold 89,433 shares of the firm’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $91.86, for a total value of $8,215,315.38. Following the completion of the transaction, the chief executive officer directly owned 869,881 shares in the company, valued at $79,907,268.66. The trade was a 9.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Stock Up 2.7%

Shares of Kiniksa Pharmaceuticals International stock traded up $2.49 during trading hours on Tuesday, reaching $93.29. 1,021,631 shares of the stock traded hands, compared to its average volume of 897,528. The company has a 50 day moving average price of $79.67 and a 200 day moving average price of $60.56. The firm has a market capitalization of $7.28 billion, a price-to-earnings ratio of 71.76 and a beta of 0.07. Kiniksa Pharmaceuticals International, plc has a one year low of $37.02 and a one year high of $98.48.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA – Get Free Report) last issued its quarterly earnings data on Tuesday, October 27th. The company reported $0.56 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. The firm had revenue of $285.97 million for the quarter, compared to analysts’ expectations of $260.66 million. Sell-side analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.30 earnings per share for the current year.

Key Stories Impacting Kiniksa Pharmaceuticals International

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

  • Negative Sentiment: Across October 30 and November 2, CAO Michael Megna, COO Ross Moat, CFO Mark Ragosa and insider John Paolini reported sales totaling about 272,600 shares, worth approximately $25.4 million. The selling could weigh on sentiment or temper the stock’s recent momentum. However, each transaction was made under a pre-arranged Rule 10b5-1 plan, so it is not necessarily a response to new company developments. Megna SEC filing Moat SEC filing Paolini SEC filing Ragosa SEC filing

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Large investors have recently added to or reduced their stakes in the company. Allworth Financial LP boosted its position in shares of Kiniksa Pharmaceuticals International by 42.0% in the second quarter. Allworth Financial LP now owns 453 shares of the company’s stock worth $29,000 after purchasing an additional 134 shares during the period. Arizona State Retirement System increased its stake in shares of Kiniksa Pharmaceuticals International by 2.1% in the second quarter. Arizona State Retirement System now owns 10,132 shares of the company’s stock worth $648,000 after purchasing an additional 209 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Kiniksa Pharmaceuticals International by 21.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,278 shares of the company’s stock valued at $95,000 after purchasing an additional 223 shares during the period. Commonwealth Equity Services LLC raised its position in shares of Kiniksa Pharmaceuticals International by 2.2% during the 3rd quarter. Commonwealth Equity Services LLC now owns 10,871 shares of the company’s stock valued at $811,000 after purchasing an additional 237 shares during the period. Finally, First Trust Advisors LP raised its position in shares of Kiniksa Pharmaceuticals International by 3.1% during the 1st quarter. First Trust Advisors LP now owns 9,876 shares of the company’s stock valued at $476,000 after purchasing an additional 293 shares during the period. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Canaccord Genuity Group increased their price target on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Zacks Research lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 30th. JPMorgan Chase & Co. raised their target price on Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the stock an “overweight” rating in a report on Friday. Wedbush boosted their price target on Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the company an “outperform” rating in a report on Wednesday, October 28th. Finally, Citigroup boosted their price target on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday, July 29th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $100.57.

View Our Latest Report on Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International Company Profile

(Get Free Report)

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.

Featured Articles